Organization | Adocia

Adocia Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Lyon France (2005)

Status: No NME R&D (2005)

Organization Overview

First Clinical Trial

2010

NCT01098357

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Adocia

Active Ingredients

Drugs in Phase 3 Trials (1)

becaplermin (regranex) (2 trials)

Drugs in Phase 2 Trials (4)

insulin aspart (Novolog) (1 trial)

insulin human (humulin) (6 trials)

insulin lispro (humalog) (25 trials)

pramlintide (symlin) (4 trials)

Drugs in Phase 1 Trials (2)

glucagon (1 trial)

insulin glargine (toujeo) (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1)

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Ulcer (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 29
# of Trial APIs: 7